Skip to content
Back to Investors
Uo

University of Oxford

Government

Portfolio

6

companies

Investment by month

By category

  • Uncategorised£52.3M
  • AgriTech£35.0M
  • CleanTech£20.8M
  • MedTech£15.3M
  • AI/ML£14.5M

By location

  • Oxford£138M

Portfolio companies

F

FluoRok

FluoRok develops sustainable technologies for manufacturing fluorochemicals.

MT

MoA Technology

MoA Technology develops next-generation herbicides to combat global weed resistance.

Navenio

Navenio

Navenio provides indoor location technology and task allocation software to improve healthcare workflow efficiency.

O

OXCCU

Converting waste gases directly into sustainable aviation fuel with a patented iron-based catalyst.

Oxford Endovascular

Oxford Endovascular

Oxford Endovascular develops origami-inspired medical devices for brain aneurysm treatment.

WB

Wild Bioscience

Wild Bioscience develops climate-resilient crop varieties using evolutionary biology and artificial intelligence.


Recent investments

Series A
$60.0M

The round was led by the Ellison Institute of Technology and will fund research and commercial expansion.

"Advancing agriculture has limitless potential to help people and the planet. So to achieve meaningful, scalable impact, we need the right investors who are truly aligned with that big vision. I’m deeply grateful to EIT and to our current investors for sharing our excitement about what we’ve accomplished so far, and for their united support as we embark on this ambitious growth journey together."
— Ross Hendron, Co-Founder and CEO
Other
£7.7M

The oversubscribed round was led by BGF and Green Generation Fund to support team growth and facility expansion.

"We are delighted to welcome BGF and Green Generation Fund along with Volta Energy Technologies to our investor base. Their experience of building successful break-through technology businesses in battery and sustainable technologies will be invaluable. With an outstanding investor syndicate to support us, we continue our mission to make fluorochemicals production safer, cheaper, and more sustainable. This investment will play a huge part in our journey to scale and commercialise our proprietary technology with key partners across the global fluorochemical supply chain, and in accelerating the development of a technology that can provide a reliable and localised supply of a key component of Li-ion batteries."
— Gabriele Pupo, CEO
Series A
£8.0M

Parkwalk Advisors spearheaded the round to help the medical technology company prepare for human trials.

"With the support of our investors, we are on the cusp of revolutionising brain aneurysm treatment. Our team is dedicated to working with regulators, medical professionals, and industry experts to bring this product to market and address a condition impacting countless individuals worldwide."
— Mike Karim, CEO
Series A
£5.0M

The funding round was led by Oxford Science Enterprises to support growth in the US and UK markets.

"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."
— Heather Roxborough, senior partner of Health Tech